Search results for "Injuries"

showing 10 items of 638 documents

Neuroprotection by erythropoietin administration after experimental traumatic brain injury.

2007

A large body of evidence indicates that the hormone erythropoietin (EPO) exerts beneficial effects in the central nervous system (CNS). To date, EPO's effect has been assessed in several experimental models of brain and spinal cord injury. This study was conducted to validate whether treatment with recombinant human EPO (rHuEPO) would limit the extent of injury following experimental TBI. Experimental TBI was induced in rats by a cryogenic injury model. rHuEPO or placebo was injected intraperitoneally immediately after the injury and then every 8 h until 2 or 14 days. Forty-eight hours after injury brain water content, an indicator of brain edema, was measured with the wet-dry method and bl…

MaleTime FactorsBrain EdemaFunctional LateralityRats Sprague-Dawleychemistry.chemical_compoundTraumatic brain injuryMedicineAnalysis of Variance Animals Blood-Brain Barrier; drug effects Brain Edema; drug therapy/etiology Brain Infarction; drug therapy/etiology Brain Injuries; complications/drug therapy Disease Models; Animal Erythropoietin; administration /&/ dosage Evans Blue; diagnostic use Functional Laterality Humans Male Neurologic Examination Neuroprotective Agents; administration /&/ dosage Rats Rats; Sprague-Dawley Reaction Time; drug effects Recombinant Proteins Time Factorsadministration /&/ dosageSpinal cord injuryEvans BlueNeurologic ExaminationGeneral Neuroscienceexperimental models of brain and spinal cord injuryExtravasationNeuroprotectionRecombinant Proteinsmedicine.anatomical_structureNeuroprotective AgentsBlood-Brain BarrierAnesthesiadiagnostic usemedicine.drugEvans BlueBrain InfarctionTraumatic brain injuryCentral nervous systemrecombinant human EPO (rHuEPO)PlaceboNeuroprotectionReaction TimeAnimalsHumansMolecular BiologyErythropoietinAnalysis of VarianceNeuroscience (all)business.industryAnimaldrug therapy/etiologymedicine.diseaseRatsDisease Models AnimalchemistryErythropoietindrug effectsBrain InjuriesDisease Modelsrecombinant human EPO (rHuEPO); experimental models of brain and spinal cord injury; NeuroprotectionNeurology (clinical)Sprague-Dawleybusinesscomplications/drug therapyDevelopmental BiologyBrain research
researchProduct

Neuroprotective potential of erythropoietin and darbepoetin alfa in an experimental model of sciatic nerve injury. Laboratory investigation.

2007

Object The objectives of this study were to examine whether the systemic administration of recombinant human erythropoietin (rHuEPO) and its long-lasting derivative darbepoetin alfa expedited functional recovery in a rat model of sciatic nerve injury, and to compare the effects of these agents in the model. Methods Thirty male Sprague–Dawley rats received a crush injury to the left sciatic nerve and subsequently underwent either placebo treatment, daily injections of rHuEPO, or weekly injections of darbepoetin alfa. Results Both rHuEPO and darbepoetin alfa were effective in reducing neurological impairment and improving compound muscle action potentials following nerve injury. Darbepoetin …

MaleTime FactorsDarbepoetin alfaNerve CrushAction PotentialsPlaceboDrug Administration ScheduleRats Sprague-Dawleyadministration /&/ dosage/pharmacologymedicineAnimalsHumansDarbepoetin alfaMuscle SkeletalErythropoietinERYTHROPOIETINdrug effects/injuries/physiopathologySettore MED/27 - Neurochirurgiabusiness.industryAction Potentials; drug effects Animals Drug Administration Schedule Erythropoietin; administration /&/ dosage/analogs /&/ derivatives/pharmacology Humans Male Muscle; Skeletal; physiopathology Nerve Crush Neuroprotective Agents; administration /&/ dosage/pharmacology Rats Rats; Sprague-Dawley Recombinant Proteins Recovery of Function; drug effects Sciatic Nerve; drug effects/injuries/physiopathology Time FactorsGeneral MedicineSkeletalRecovery of FunctionNerve injurySciatic nerve injurymedicine.diseaseadministration /&/ dosage/analogs /&/ derivatives/pharmacologySciatic NerveNeuroprotectionRecombinant ProteinsRatsNeuroprotective AgentsNeurologyErythropoietinPeripheral nerve injuryAnesthesiadrug effectsPeripheral nerve injuryCrush injuryMuscleSurgeryNeurology (clinical)Sciatic nerveSprague-Dawleymedicine.symptomphysiopathologybusinessmedicine.drug
researchProduct

[Spontaneous pneumoperitoneum: a case secondary to thoracic trauma].

2007

Spontaneous pneumoperitoneum is the radiographic manifestation of free air in the peritoneal cavity without visceral perforations and peritoneal signs, and it occurs in about 10% of the cases of pneumoperitoneum. The etiology can be postoperative, thoracic, abdominal, gynecologic, idiopathic; it generally introduces a benign evolution and does not require surgical treatment but just a conservative approach. The authors describe here a case of spontaneous pneumoperitoneum secondary to thoracic trauma. This case is interesting for the occurrence of pneumoperitoneum without clinical peritoneal signs such as fever and leucocytosis, after closed thoracic trauma in absence of pneumothoracic and p…

MaleTime FactorsThoracic InjuriesInfant NewbornOxygen Inhalation TherapyWounds NonpenetratingPNEUMOPERITONEUM - THORACIC INJURY - THORACIC DISEASES - PERITONEAL DISEASESAnti-Bacterial AgentsSettore MED/18 - Chirurgia GeneraleTreatment OutcomePneumoperitoneumHumansAccidental FallsRadiography ThoracicDiureticsAgedFollow-Up StudiesMinerva chirurgica
researchProduct

Cranioplasty with autologous bone flaps cryopreserved with Dimethylsulphoxide : does tissue processing matter

2021

Este artículo se encuentra disponible en la siguiente URL: https://www.sciencedirect.com/science/article/abs/pii/S1878875021001625?via%3Dihub En este artículo de investigación también participan: Dolores Ocete, Lucas Aranda, Ana Melero, Antonio J. Guillot, Nuria Yagüe y Carlos Botella. Este es el pre-print del siguiente artículo: Mirabet, V., García, D., Roca, A., Quiroz, A. R., Antón, J., Rodríguez-Cadarso, M., Ocete, D., Aranda, L., Melero, A., Guillot, A. J., Yagüe, N., Guillén, I. & Botella, C. (2021). Cranioplasty with autologous bone flaps cryopreserved with Dimethylsulphoxide: does tissue processing matter. World Neurosurgery, vol. 149 (may.), pp. e582?e591, que se ha publicado de fo…

MaleTime Factorsmedicine.medical_treatmentBrain EdemaSurgical Flaps0302 clinical medicineCryoprotective AgentsPostoperative ComplicationsHuesos - Crioconservación.Brain Injuries TraumaticAutograftsAutologous bone flapMiddle AgedCranioplastyResorptionAnti-Bacterial AgentsStrokeCryopreservacion of organs tissues etc.030220 oncology & carcinogenesisTissue bankVancomycinDecompressive craniectomyFemalemedicine.drugCrioconservación de órganos tejidos etc.Adultmedicine.medical_specialtyDecompressive CraniectomyAdolescentDecompressive craniectomyCráneo - Cirugía.CranioplastySkull - Surgery.03 medical and health sciencesYoung AdultmedicineHumansSurgical Wound InfectionDimethyl SulfoxideBones - Cryopreservacion.Bone ResorptionCryopreservationbusiness.industryBone storageSkullPostoperative complicationBone processingPlastic Surgery Proceduresmedicine.diseaseSurgeryHydrocephalusSurgeryNeurology (clinical)businessComplication030217 neurology & neurosurgery
researchProduct

2-Methoxyestradiol confers neuroprotection and inhibits a maladaptive HIF-1α response after traumatic brain injury in mice

2014

HIF-1α is pivotal for cellular homeostasis in response to cerebral ischemia. Pharmacological inhibition of HIF-1α may reduce secondary brain damage by targeting post-translational mechanisms associated with its proteasomal degradation and nuclear translocation. This study examined the neuroprotective effects of 2-methoxyestradiol (2ME2), the involved HIF-1α-dependent response, and alternative splicing in exon 14 of HIF-1α (HIF-1α∆Ex14) after traumatic brain injury (TBI) in mice. Intraperitoneal 2ME2 administration 30 min after TBI caused a dose-dependent reduction in secondary brain damage after 24 h. 2ME2 was physiologically tolerated, showed no effects on immune cell brain migration, and …

MaleTraumatic brain injuryBlotting WesternIschemiaCellular homeostasisBrain damagePharmacologyBiologyBiochemistryNeuroprotectionBrain IschemiaMitochondrial ProteinsMiceCellular and Molecular Neurosciencechemistry.chemical_compoundPlasminogen Activator Inhibitor 1medicineAnimalsCell NucleusNeuronsEstradiolTumor Necrosis Factor-alphaAlternative splicingMembrane ProteinsExonsHypoxia-Inducible Factor 1 alpha Subunitmedicine.diseaseImmunohistochemistryUp-RegulationMice Inbred C57BLAlternative SplicingProtein TransportNeuroprotective AgentsGene Expression RegulationchemistryBrain InjuriesPlasminogen activator inhibitor-1Tumor necrosis factor alphamedicine.symptomNeuroscienceInjections IntraperitonealSubcellular FractionsJournal of Neurochemistry
researchProduct

The antioxidative, non-psychoactive tricyclic phenothiazine reduces brain damage after experimental traumatic brain injury in mice.

2014

Abstract Oxidative stress due to free radical formation is an important mechanism of secondary brain damage following traumatic brain injury (TBI). Phenothiazine has been found to be a strong antioxidant in eukaryotic cells in vitro and in invertebrates in vivo. The present study was designed to determine the neuroprotective potency of unsubstituted phenothiazine in a paradigm of acute brain injury. Thirty minutes after pneumatic, controlled cortical impact (CCI) injury, C57BI6 mice were randomly assigned to “low dose” (3 mg/kg, LD) or “high dose” (30 mg/kg, HD) s.c. phenothiazine or vehicle treatment. Brain lesion, neurofunctional impairment, body weight, and markers of cerebral inflammati…

MaleTraumatic brain injuryGene ExpressionInflammationCell CountBrain damagePharmacologymedicine.disease_causeNeuroprotectionAntioxidantsRandom AllocationIn vivoPhenothiazinesMedicineAnimalschemistry.chemical_classificationInflammationDose-Response Relationship Drugbusiness.industryGeneral NeuroscienceCalcium-Binding ProteinsMicrofilament ProteinsBrainmedicine.diseaseMice Inbred C57BLchemistryAnesthesiaBrain InjuriesTumor necrosis factor alphamedicine.symptombusinessNeurogliaOxidative stressTricyclicNeuroscience letters
researchProduct

Propofol Impairs Neurogenesis and Neurologic Recovery and Increases Mortality Rate in Adult Rats After Traumatic Brain Injury*

2013

Objective: Limited data are available on the influence of sedation for critical care therapy with the widely used anesthetic propofol on recovery from acute traumatic brain injury. To establish the influence of propofol on endogenous neurogenesis and functional recovery after traumatic brain injury, rats were sedated with propofol either during or 2 hours after experimental traumatic brain injury. Design: Randomized controlled animal study. Setting: University research laboratory. Subjects: One hundred sixteen male Sprague Dawley rats. Interventions: Mechanical brain lesion by controlled cortical impact. Measurements and Main Results: This study investigated the dose-dependent influence of …

MaleTraumatic brain injuryNeurogenesisSedationCritical Care and Intensive Care MedicineSevofluraneRats Sprague-DawleyCognitionAnimalsHypnotics and SedativesMedicineMaze LearningPropofolDose-Response Relationship Drugbusiness.industryMortality rateNeurogenesisBrainRecovery of Functionmedicine.diseaseRatsDose–response relationshipBrain InjuriesAnesthesiaAnestheticmedicine.symptombusinessPropofolmedicine.drugCritical Care Medicine
researchProduct

Low Energy Availability is Difficult to Assess But Outcomes Have Large Impact on Bone Injury Rates in Elite Distance Athletes

2018

We aimed to (a) report energy availability (EA), metabolic/reproductive function, bone mineral density, and injury/illness rates in national/world-class female and male distance athletes and (b) investigate the robustness of various diagnostic criteria from the Female Athlete Triad (Triad), Low Energy Availability in Females Questionnaire, and relative energy deficiency in sport (RED-S) tools to identify risks associated with low EA. Athletes were distinguished according to benchmarks of reproductive function (amenorrheic [n = 13] vs. eumenorrheic [n = 22], low [lowest quartile of reference range; n = 10] versus normal testosterone [n = 14]), and EA calculated from 7-day food and training d…

MaleTriadMedicine (miscellaneous)Physiology0302 clinical medicineBone DensitySurveys and QuestionnairesOrthopedics and Sports MedicineTestosteroneAmenorrheaaineenvaihduntaTestosteroneBone mineralluustoNutrition and DieteticsTriiodothyroninebiologyGeneral MedicineQuartileAthletic InjuriesTriiodothyronineFemaleFemale athlete triadAdultluuntiheys030209 endocrinology & metabolismReference rangemetabolic hormonesBone and Bonesreproductive hormones03 medical and health sciencesYoung AdultmedicineHumansbone healthRED-SAthletesbusiness.industryMalnutritionNutritional RequirementsFemale Athlete Triad Syndrome030229 sport sciencesbiology.organism_classificationmedicine.diseasehormonitSports Nutritional Physiological PhenomenaCross-Sectional StudiesenergiansaantiAthletesbusinessEnergy IntakeEnergy MetabolismHormone
researchProduct

Perlecan-Induced Suppression of Smooth Muscle Cell Proliferation Is Mediated Through Increased Activity of the Tumor Suppressor PTEN

2004

We were interested in the elucidation of the interaction between the heparan sulfate proteoglycan, perlecan, and PTEN in the regulation of vascular smooth muscle cell (SMC) growth. We verified serum-stimulated DNA synthesis, and Akt and FAK phosphorylation were significantly reduced in SMCs overexpressing wild-type PTEN. Our previous studies showed perlecan is a potent inhibitor of serum-stimulated SMC growth. We report in the present study, compared with SMCs plated on fibronectin, serum-stimulated SMCs plated on perlecan exhibited increased PTEN activity, decreased FAK and Akt activities, and high levels of p27, consistent with SMC growth arrest. Adenoviral-mediated overexpression of cons…

MaleVascular smooth musclePhysiology:CIENCIAS MÉDICAS ::Farmacodinámica [UNESCO]Aorta ThoracicBasement MembraneCulture Media Serum-FreeMuscle Smooth VascularRats Sprague-DawleyMicePhosphorylationCells CulturedGlycosaminoglycansbiologyProtein-Tyrosine KinasesCell cycle:CIENCIAS MÉDICAS [UNESCO]musculoskeletal systemUNESCO::CIENCIAS MÉDICAS ::FarmacodinámicaUNESCO::CIENCIAS MÉDICAScardiovascular systemPhosphorylationSmooth muscle cell proliferationCardiology and Cardiovascular MedicineCell DivisionDNA ReplicationBasement membraneRecombinant Fusion ProteinsPerlecanProtein Serine-Threonine KinasesVascular injurySmooth muscle cell proliferation ; Restenosis ; Vascular injury ; Vascular development ; Basement membraneCatheterizationProto-Oncogene ProteinsAnimalsPTENProtein kinase BRestenosisCell growthVascular developmentOligonucleotides AntisenseFibronectinsRatsFibronectinFocal Adhesion Kinase 1Focal Adhesion Protein-Tyrosine Kinasesbiology.proteinCancer researchHeparitin SulfateCarotid Artery InjuriesProtein Processing Post-TranslationalProto-Oncogene Proteins c-aktHeparan Sulfate ProteoglycansCirculation Research
researchProduct

DEXAMETHASONE INTRAVITREAL IMPLANT VS RANIBIZUMAB IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRACHYTHERAPY FOR CHOROIDAL MELANOMA

2017

PURPOSE To evaluate the efficacy of an intravitreal dexamethasone (Dex) implant 0.7 mg compared with intravitreal ranibizumab (Ra) for the treatment of radiation maculopathy with macular edema secondary to plaque brachytherapy in choroidal melanoma. METHODS Eight patients were treated with intravitreal Ra, and eight patients received the Dex intravitreal implant. Visual acuity and foveal thickness were evaluated using spectral domain optical coherence tomography. RESULTS The mean calculated irradiation to the fovea and mean times from brachytherapy to maculopathy development did not differ significantly between groups. In the Ra group, a mean 7.8 ± 3.9 injections were given and the mean fol…

MaleVisual acuitygenetic structuresmedicine.medical_treatmentBrachytherapyOcular hypertensionAngiogenesis InhibitorsDrug Implant0302 clinical medicineGlucocorticoidDexamethasone Intravitreal ImplantRadiation InjurieMelanomaDrug ImplantsChoroid NeoplasmsGeneral MedicineMiddle AgedIntravitreal InjectionsDrug Therapy CombinationFemalemedicine.symptommedicine.drugAngiogenesis InhibitorHumanmedicine.medical_specialtyBrachytherapydexamethasone03 medical and health sciencesradiation maculopathyOphthalmologyRanibizumabmedicineHumanschoroidal melanomaRadiation InjuriesGlucocorticoidsMacular edemaDexamethasoneAgedRetrospective Studiesmacular edemabusiness.industryIntravitreal Injectionmedicine.diseaseeye diseasesOphthalmology030221 ophthalmology & optometryMaculopathyRanibizumabbusinessChoroid Neoplasm030217 neurology & neurosurgery
researchProduct